Titan Pharmaceuticals Inc (TTNP)

[Doctor Detroit]

T-3


From Zacks:


"In Western countries approximately 0.3 to 0.4% of the population have overt hypothyroidism. Subclinical hypothyroidism afflicts from 4.3 to 8.5% of the population.9 The disease is much more common in women than in men, approximately 4 to 5 times10 depending on the definition of the disease. Our model anticipates a population of 14 million hypothyroid sufferers in the United States. Approximately 16% of this number will require T3, either as combination therapy in conjunction with T4 (14%) or as T3 monotherapy (2%). Penetration of Titan s T3 implant is anticipated to start out slowly at 0.4% in the first year of commercialization and rise over 6% over the next several years."

Thoughts-

16% of 14 million patient population = 2.24 million patients

Cost of treatment, after deductions, is expected to be $6,000 a year.

Year one= 0.4% of 2.24 million = 9,000 patients x $6,000 = $54 million

Maturity= 6% of 2.24 million = 134,000 x $6,000 = $804 million.